Skip to main content
Premium Trial:

Request an Annual Quote

Cancer in His Sights

In a series, the New York Times profiles the work of Keith Flaherty, an oncologist at the University of Pennsylvania, who has evangelized a targeted approach to treating cancer. The first part follows the highs and lows of clinical trials after Flaherty jumped headlong into testing drugs targeting B-RAF mutations in cancer. His first drug from Bayer failed and finding the proper does for a second from Plexxikon has taken a few re-formulations, but holds a glimmer of promise: he has his first responder.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.